Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

Citation: Haile PA, Casillas LN, Votta BJ, Wang GZ, Charnley AK, Dong X, Bury MJ, Romano JJ, Mehlmann JF, King BW, Erhard KF, Hanning CR, Lipshutz DB, Desai BM, Capriotti CA, Schaeffer MC, Berger SB, Mahajan MK, Reilly MA, Nagilla R, Rivera EJ, Sun HH, Kenna JK, Beal AM, Ouellette MT, Kelly M, Stemp G, Convery MA, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Marquis RW.: Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem, Volume 62 (14), 2019
Authors: Beal AM, Berger SB, Bertin J, Bury MJ, Capriotti CA, Casillas LN, Charnley AK, Convery MA, Desai BM, Dong X, Erhard KF, Gough PJ, Haile PA, Hanning CR, Kelly M, Kenna JK, King BW, Lipshutz DB, MacDonald TT, Mahajan MK, Marquis RW., Mehlmann JF, Nagilla R, Ouellette MT, Reilly MA, Rivera EJ, Romano JJ, Schaeffer MC, Stemp G, Sun HH, Vossenkämper A, Votta BJ, Wang GZ
Journal: J Med Chem
Year: 2019
DOI: 10.1021/acs.jmedchem.9b00575
PubMed: 31265286
Machine-readable: REST API RDF

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.